How much has Big Pharma given to presidential candidates Donald Trump (left) and Kamala Harris? (GV Wire Composite/Paul Marshall)
Share
Getting your Trinity Audio player ready...
|
Kamala Harris is Big Pharma’s big candidate for president.
Data from Open Secrets show the vice president tops the list of federal candidates receiving campaign contributions from the pharmaceutical industry — at $5.7 million.
That is nearly six times more than No.2 on the list — former President Donald Trump at a shade under $1 million.
The industry had traditionally spent more for Republicans, but that turned around in 2020, with Democrats taking home more. Open Secrets reports Democrats receiving $29 million compared to $21 million for Republicans in 2024.
Medicare price negotiations are a top federal concern for the presidential candidates, reports Amy Baxter of industry news publication PharmaVoice.
No Central Valley Candidates in Big Pharma Top 20
Big Pharma, as part of the health category, is the fifth biggest industry sector that contributes to campaign cash. Finance/insurance/real estate tops the list at $2 billion.
Abbott Laboratories — makers of Pedialyte, and FreeStyle Libre — is the top federal Big Pharma spender in the 2024 elections at $5 million.
No Central Valley congressional candidate made the Top-20 list for Big Pharma contributions.
RELATED TOPICS:
Nick Chubb Plows Through Heavy Snow as Browns Beat Steelers
16 minutes ago
German Auto Supplier Bosch to Cut 5,500 Jobs in Further Sign of Carmakers’ Woes
21 minutes ago
Woman Found Dead in Fresno. Homicide Investigation Underway.
21 minutes ago
Supreme Court Allows Multibillion-Dollar Class Action to Proceed Against Meta
26 minutes ago
Brock Purdy’s Status for the 49ers in Doubt This Week Because of Sore Shoulder
31 minutes ago
Amazon to Invest an Additional $4 Billion in AI Startup Anthropic
1 hour ago
Northern California Gets Record Rain and Heavy Snow. Many Have Been in the Dark for Days in Seattle
1 hour ago
Many in Gaza Are Eating Just Once a Day, as Hunger Spreads Amid Aid Issues